On August 17, JOINN (06127) rose 6.22% in regular trading, trading at 26.72 HKD/share, with turnover of 50.31 million HKD.

On the news front, the company recently disclosed on its investor relations platform that its backlog stood at 3.1 billion RMB as of Q1 end. Legacy low-price orders have been clearing in an orderly manner since industry demand recovered in late Q4 of the prior year. Notably, non-human primate experimental animal prices and new order signing prices have both rebounded compared to earlier periods.

The broader CXO sector rallied in tandem, with institutional research reports citing clear upward signals in industry prosperity driven by a global biotech financing recovery. Within the Life Sciences Tools and Services sector, GENSCRIPT BIO rose 5.55%, WUXI BIO rose 4.92%, WUXI APPTEC rose 4.46%, XTALPI rose 3.37%, and INSILICO rose 3.01%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)